Zejula, Revatio Advisory Committee Meetings Cancelled; Palovarotene Panel Postponed

Panel to review overall survival data on GSK’s Zejula for ovarian cancer ‘is no longer needed,’ US FDA says. Meeting to consider pediatric indication for Viatris’ Revatio was also cancelled though sNDA remains active. FDA to review new information on Ipsen’s palovarotene clinical trial data.

Cancelled meeting
FDA cancels two advisory committee meetings, including 22 November consideration of Zejula sNDA, and postpones another • Source: Shutterstock

The US Food and Drug Administration’s hectic fall schedule of advisory committee meetings has gotten lighter since the agency cancelled two meetings and postponed another.

The Oncologic Drugs Advisory Committee meeting set for 22 November to consider overall survival data on GlaxoSmithKline Pharmaceuticals Ltd.’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers